Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs

by Barry101 | Jan 31, 2018 | Press Release

Three Studies Reviewed at Keystone Symposium on Emerging Technologies in Vaccine Discovery and Development Demonstrate Production of Antibodies Against Highly Pathogenic Strains of Avian Flu Viruses with Human Pandemic Potential with Seasonal VaccinesBANFF, Alberta,...

Hemispherx to Present at the BIO CEO & Investor Conference

by Barry101 | Jan 29, 2018 | Press Release

ORLANDO, Fla., Jan. 29, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the BIO CEO & Investor Conference on Monday, February 12th at 9:15AM ET (the time may be...

Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection

by Barry101 | Jan 26, 2018 | Press Release

Scheduled for January 30 at the Keystone Symposia on Molecular and Cellular BiologyORLANDO, Fla., Jan. 26, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announces that William Mitchell, MD, PhD, Professor of...

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

by Barry101 | Jan 25, 2018 | Press Release

Multiple Studies Continue to Demonstrate Broad Immunotherapeutic Properties of Hemispherx’s AmpligenMIAMI, Jan. 25, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice chairman...

Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.

by Barry101 | Jan 23, 2018 | Press Release

Ampligen® has orphan drug status in the U.S. for treatment of Myalgic Encephalomyelitis/Chronic Fatigue SyndromeORLANDO, Fla., Jan. 23, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today commented on the...